CDZ173
Biological
NOVARTIS PHARMACEUTICALS CORPORATION
Total Payments
$851,049
Transactions
8
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $235,694 | 1 | 0 |
| 2019 | $229,239 | 1 | 0 |
| 2018 | $101,626 | 2 | 1 |
| 2017 | $284,492 | 4 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $851,049 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| POC STUDY IN APDS ACTIVATED PI3K DELTA SYNDROME | Novartis Pharmaceuticals Corporation | $566,190 | 0 |
| POC STUDY IN APDS ACTIVATED PI3K DELTA SYNDROME | NOVARTIS PHARMACEUTICALS CORPORATION | $276,701 | 1 |
| A SINGLE CENTER OPEN LABEL SINGLE SEQUENCE CROSSOVER STUDY TO INVESTIGATE THE EFFECT OF ITRACONAZOLE AND QUINIDINE ON THE PHARMACOKINETICS OF ORAL CDZ173 IN HEALTHY SUBJECTS | Novartis Pharmaceuticals Corporation | $7,710 | 0 |
| AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY EFFICACY AND PHARMACOKINETICS OF CDZ173 IN PATIENTS WITH APDS PASLI ACTIVATED PHOSPHOINOSITIDE 3 KINASE DELTA SYNDROME P1108 ACTIVATING MUTATION CAUSING SENESCENT T CELLS LYMPHADENOPATHY AND IMMUNODEFICIENCY | NOVARTIS PHARMACEUTICALS CORPORATION | $448.75 | 2 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $573,900
- NOVARTIS PHARMACEUTICALS CORPORATION $277,150
Product Information
- Type Biological
- Total Payments $851,049
- Total Doctors 3
- Transactions 8
About CDZ173
CDZ173 is a biological associated with $851,049 in payments to 3 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is NOVARTIS PHARMACEUTICALS CORPORATION.
Payment data is available from 2017 to 2020. In 2020, $235,694 was paid across 1 transactions to 0 doctors.
The most common payment nature for CDZ173 is "Unspecified" ($851,049, 100.0% of total).
CDZ173 is associated with 4 research studies, including "POC STUDY IN APDS ACTIVATED PI3K DELTA SYNDROME" ($566,190).